Comparative Pharmacology
Head-to-head clinical analysis: AMPHOTEC versus EXTINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHOTEC versus EXTINA.
AMPHOTEC vs EXTINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.
Antifungal agent that inhibits the enzyme 14α-demethylase, blocking the conversion of lanosterol to ergosterol, an essential component of fungal cell membranes.
Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.
2.5% to 3.5% solution applied topically twice daily for 4 weeks.
None Documented
None Documented
Terminal half-life: 24-48 hours (up to 7 days in hepatic impairment). Long half-life allows once-daily dosing.
Terminal elimination half-life is approximately 24-32 hours in adults, allowing once-daily dosing. Half-life may be prolonged in patients with renal impairment.
Biliary/fecal: ~90% unchanged; renal: <10% (mainly as metabolite).
Primarily renal excretion of unchanged drug (approximately 80-90% of the absorbed dose), with minor hepatic metabolism and fecal elimination (<10%).
Category C
Category C
Antifungal
Antifungal